A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD).
Findings from the Phase III trial were presented June 16 at the European Hematology Society’s 23rd Congress in Stockholm by Jorge Cortes,...
Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors...
Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug,...
The University of Texas MD Anderson Cancer Center will host its 20th annual Making Cancer History® seminar in Aspen, 10 a.m.-12 p.m. Monday, July 23 at Aspen Meadows Resort’s Paepcke Auditorium, 1000 N. Third St. The event is free and open to the public.
As a token of appreciation for the Aspen community’s support over the past two decades, MD Anderson also will provide an outdoor yoga activity, 8:30-9:30 a.m. July 23, with registration...
In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center adding the PARP inhibitor veliparib...
Recognizing that vaccination rates for the human papillomavirus (HPV) remain low across the U.S., particularly in Texas, The University of...
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family Fellows. As...